Scarica l'app Stockscreener
19.63
0.31%
0.06
Pre-mercato:
19.67
0.04
+0.20%
Precedente Chiudi:
$19.57
Aprire:
$20.57
Volume 24 ore:
572.42K
Relative Volume:
2.77
Capitalizzazione di mercato:
$520.70M
Reddito:
-
Utile/perdita netta:
$-29.59M
Rapporto P/E:
-15.40
EPS:
-1.275
Flusso di cassa netto:
$-18.35M
1 W Prestazione:
-31.20%
1M Prestazione:
+105.77%
6M Prestazione:
+139.39%
1 anno Prestazione:
+160.34%
Intervallo 1D:
$19.61
$20.74
Intervallo di 1 settimana:
$17.77
$21.24
Portata 52W:
$5.55
$29.27
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Nome
Nuvectis Pharma Inc
Settore
Industria
Telefono
360-837-7232
Indirizzo
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
19.63 | 487.80M | 0 | -29.59M | -18.35M | -1.275 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-02 | Iniziato | Maxim Group | Buy |
| 2025-03-17 | Iniziato | Laidlaw | Buy |
| 2022-07-13 | Iniziato | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Borsa (NVCT) Ultime notizie
Nuvectis Pharma announces public share offering to support drug programs - MSN
Insider Buying: Ron Bentsur Acquires Additional Shares of Nuvect - GuruFocus
Nuvectis Pharma CEO Ron Bentsur buys $250,000 in company stock By Investing.com - Investing.com South Africa
[Form 4] Nuvectis Pharma, Inc. Insider Trading Activity - Stock Titan
Form 4 Nuvectis Pharma Inc For: 1 July By Investing.com - Investing.com India
Nuvectis Pharma 10% owner Mosseri buys $916k in shares - Investing.com UK
Nuvectis Pharma (NVCT) CEO Ron Bentsur buys $250,000 in shares - Stock Titan
Nuvectis: 'Hold' On NXP800 Removal And Newly Licensed Candidates (NASDAQ:NVCT) - Seeking Alpha
What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Nuvectis Raises $100M for Oncology Pivot - AllSci
Nuvectis Pharma Announces Major Public Equity Offering - TipRanks
Form 424B5 Nuvectis Pharma Inc For: 30 June By Investing.com - Investing.com Canada
Nuvectis Pharma Sets 5M-Share, $20 Offering; ~$93M Net, Cantor Fitzgerald Underwriter - TradingView
Nuvectis Pharma (NASDAQ: NVCT) to raise $100M in stock sale - Stock Titan
Nuvectis Pharma (NVCT) files $100M offering; 5.0M shares at $20.00 - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Nuvectis gains two experimental drugs in licensing deal with China's Haisco - MSN
Nuvectis shares continue to rally after $1.46B Haisco deal - BioWorld News
Nuvectis Pharma shares slide after pricing $100 million discounted stock offering (NVCT) - Yahoo Finance
Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stoc - Benzinga
Nuvectis Pharma stock tumbles 25% on discounted offering By Investing.com - Investing.com Canada
Nuvectis Pharma Prices $100 Million Secondary Stock Offering; Shares Down Pre-Bell - Moomoo
Nuvectis Pharma's $100 Million Offering: Dilution at a Discount Amidst Pipeline Hopes - Kavout | AI
Nuvectis locks in $100M from 5 million-share stock sale - Stock Titan
Nuvectis Pharma Intends to Use Net Proceeds From Offering to Advance Development Programs >NVCT - Moomoo
Nuvectis Pharma prices $100 million public offering at $20/share By Investing.com - Investing.com Australia
Nuvectis Pharma Prices $100 Million Underwritten Public Offering of Common Stock - Quiver Quantitative
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock - GlobeNewswire
Form 424B5 Nuvectis Pharma Inc For: 29 June - Investing.com UK
Form 424B5 Nuvectis Pharma Inc For: 29 June By Investing.com - Investing.com Australia
Nuvectis Pharma launches public offering of common stock By Investing.com - Investing.com Australia
Nuvectis Pharma stock tumbles on public offering launch By Investing.com - Investing.com South Africa
Nuvectis Pharma prices $100 million public offering of common stock - scanx.trade
Nuvectis Pharma Suspends Equity Offering Program Under Agreement - TipRanks
Nuvectis (NASDAQ: NVCT) prelim prospectus; Haisco license, $20M upfront - Stock Titan
Nuvectis Pharma launches public offering of common stock - Investing.com
Nuvectis Pharma Launches Proposed Public Stock Offering - Moomoo
Nuvectis Pharma stock tumbles on public offering launch - Investing.com UK
Nuvectis Pharma moves to raise capital through proposed public stock sale - Traders Union
Nuvectis Pharma (NASDAQ: NVCT) cuts and suspends $5M ATM share sales - Stock Titan
Nuvectis Pharma seeks fresh capital for cancer and immune programs - Stock Titan
Nuvectis Pharma, Inc.(NasdaqCM: NVCT) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Nuvectis Pharma Up 97%, Insider Buyers Are Up 344% - simplywall.st
Enterprise value to revenue forward of Nuvectis Pharma, Inc. – NASDAQ:NVCT - TradingView
Enterprise value to EBIT forward of Nuvectis Pharma, Inc. – NASDAQ:NVCT - TradingView
Price to book forward of Nuvectis Pharma, Inc. – NASDAQ:NVCT - TradingView
What makes Nuvectis Pharma (NVCT) a new buy stock - MSN
What Makes Nuvectis Pharma (NVCT) a New Buy Stock - Yahoo Finance
Nuvectis Pharma, Inc. Actuals & Estimates (NASDAQ:NVCT) - TradingView
Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade - MSN
NVCT Forecast — Price Target — Prediction for 2027 - TradingView
Nuvectis Pharma Inc Azioni (NVCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nuvectis Pharma Inc Azioni (NVCT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BENTSUR RON | Chairman & CEO |
Jun 30 '26 |
Buy |
20.00 |
12,500 |
250,000 |
3,688,424 |
| BENTSUR RON | Chairman & CEO |
Nov 05 '25 |
Buy |
5.72 |
5,000 |
28,600 |
3,525,924 |
| Sanchez Juan | Director |
Nov 05 '25 |
Buy |
5.79 |
13,000 |
75,270 |
78,150 |
| Kaplan Matthew L. | Director |
Nov 05 '25 |
Buy |
5.84 |
11,000 |
64,240 |
124,760 |
| Mosseri Marlio Charles | 10% Owner |
Oct 27 '25 |
Buy |
6.28 |
72,836 |
457,410 |
3,136,576 |
| Mosseri Marlio Charles | 10% Owner |
Oct 23 '25 |
Buy |
6.06 |
46,900 |
284,214 |
3,028,706 |
| Mosseri Marlio Charles | 10% Owner |
Oct 24 '25 |
Buy |
6.15 |
35,034 |
215,459 |
3,063,740 |
0.05%
0.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):